Head and Neck Cancer Therapies: Current and Innovative Options
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 176
Special Issue Editor
Special Issue Information
Dear Colleagues,
The HNSCC therapeutic landscape is currently in a state of high-stakes flux. While we celebrate the "immunotherapy revolution," the bedside reality remains tethered to the toxicities of decades-old regimens. This Special Issue seeks to host a rigorous dialog on innovation, interrogating the following:
- LA-HNSCC Neoadjuvant Pivots: Does the surge in perioperative immunotherapy truly redefine organ preservation, or does the disconnect between pathologic complete response (pCR) and surgical margin safety pose new clinical risks?
- Molecular Warheads and Dual Targeting: Beyond simple inhibition, how are ADCs managing the delicate balance between bystander effects and off-target payload toxicities? Are bispecific antibodies effectively achieving dual-pathway inhibition without the prohibitive adverse events seen in early-phase trials?
- The HPV Paradox: Refining de-intensification—moving from "can we do less?" to "how do we do less safely?"
- Underserved Malignancies: We turn our focus lastly—but crucially—to salivary gland cancers and sinonasal carcinomas, where therapeutic breakthroughs have historically lagged behind.
Dr. Ye Guo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- multimodal therapy
- precision oncology
- immunotherapy
- antibody–drug conjugates
- bispecific antibodies
- HPV
- salivary gland cancers and sinonasal carcinomas
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
